Research of CET is supported by grants from the European Commission (Marie Curie International Training Network; grant agreement number 860197 [MIRIADE]); Innovative Medicines Initiatives (IMIs) 3TR (Horizon 2020; grant number 831434) and European Platform for Neurodegenerative Diseases (IMI 2 Joint Undertaking under grant agreement number 101034344); EU Joint Programme – Neurodegenerative Disease Research (bPRIDE); National Multiple Sclerosis Society (Progressive MS Alliance); Health~Holland; Dutch Research Council (ZonMw); Alzheimer's Drug Discovery Foundation; The Selfridges Group Foundation; Alzheimer Nederland; and Alzheimer's Association. CET is a recipient of ABOARD, which is a public–private partnership (PPP) receiving funding from ZonMw (number 73305095007) and Health~Holland (Topsector Life Sciences & Health; PPP allowance; number LSHM20106). ABOARD also receives funding from Edwin Bouw Fonds and Gieskes-Strijbis Fonds. CET has a collaboration contract with ADx NeuroSciences, Quanterix, and Eli Lilly. CET performed contract research for AC Immune, Axon Neuroscience, LabConnect, BIORCHESTRA, BrainStorm Cell Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, FUJIFILM Toyama Chemical, and Vivoryon Therapeutics; and had speaker contracts from Roche, Grifols, and Novo Nordisk. CET serves on the editorial boards of Springer Healthcare, Alzheimer's Research & Therapy, and Neurology: Neuroimmunology & Neuroinflammation, and is an Editor of Cerebrospinal Fluid Biomarkers (Springer). JM received a research grant by Alzheimer Nederland (number WE.03-2020-13).